
-
Romania names interim premier as turmoil deepens
-
DoorDash agrees £2.9 billion takeover of Deliveroo
-
Dollar recovers some losses, stocks mixed as traders eye tariff deals
-
Hamas says no point in further Gaza truce talks
-
'Aussiewood' courts Hollywood as Trump film tariffs loom
-
How a privately owned city in Kenya took on corrupt officials
-
Ozempic slimming craze sweeps Kosovo despite side effects
-
Drone strikes rock Port Sudan in third day of attacks
-
US President Trump and Canada's Carney set for high-stakes meeting
-
Philips turns in a profit but China, tariffs weigh
-
Drones hit Port Sudan airport in third day of attacks
-
Australian mushroom murder suspect rejected help preparing meal: witness
-
Jokic-inspired Nuggets stun Thunder, Knicks down Celtics
-
India's woman fighter pilot trailblazer eyes space
-
'Shared dream': China celebrates Zhao's world snooker breakthrough
-
Wait for Vatican white smoke fires up social media
-
Sinner leading the charge in golden era for Italian tennis
-
Donnarumma stands tall on PSG's Champions League run
-
Dollar recovers some losses, stocks gain as traders eye tariff deals
-
US aid cuts push Bangladesh's health sector to the edge
-
Prayers, pride in Philippine papal contender's hometown
-
Germany's Merz to launch new govt in times of Trump turbulence
-
Brunson sparks Knicks in comeback win over Celtics
-
All roads lead to Rome Open for Sinner after doping ban
-
French Resistance members reunited 80 years after end of WWII
-
Arsenal must 'stick together' in PSG showdown: Odegaard
-
New Zealand PM proposes banning under-16s from social media
-
Rihanna reveals third pregnancy on Met Gala night
-
Trump orders curb on virus research he blames for Covid pandemic
-
'Makes no sense': Hollywood shocked by Trump's film tariffs announcement
-
First day of jury selection wraps in Sean Combs sex crimes trial
-
Dominican Republic reports sharp rise in Haitian migrant deportations
-
Mennonite communities raise hackles in Peruvian Amazon
-
Dominican Republican reports sharp rise in Haitian migrant deportations
-
Stars shine at Met Gala, showcasing Black dandyism
-
Ireland captain Doris doubtful for Lions tour due to shoulder injury
-
Pentagon chief orders 20% cut in number of top officers
-
'New superstar' Zhao's world title heralds Chinese snooker revolution
-
OpenAI abandons plan to become for-profit company
-
Ford sees $1.5 bn tariff hit this year, suspends 2025 forecast
-
Snooker star Zhao: from ban to Chinese sporting history
-
Zhao makes history as China's first World Snooker champion
-
Brazilian ritual root gets second life as potential anti-depressant
-
Israel says 'most' Gazans to be displaced in expanded operation
-
Israel strikes Yemen after Huthi attack on Ben Gurion airport
-
'It's time': Popovich passes Spurs torch to Johnson
-
Cummins heroics in vain as rain forces Hyderabad out of IPL playoff race
-
Huthis say US, Israel bomb Yemen after strike on Israeli airport
-
Lewandowski on bench for Barca's showdown with Inter, says coach Flick
-
Pricing birdsong: EU mulls nature credits to help biodiversity

Ozempic slimming craze sweeps Kosovo despite side effects
Kosovo influencer Tringa Kadriu sees the slimming drug Ozempic as a chance to shed excess pounds -- and she is not the only one in her Balkan nation, where more than half the population is overweight.
"I want to lose 15-16 kilos (33-35 pounds) in two months," Kadriu, 29, told AFP, "and then I'll continue with fitness".
Ozempic, approved in the United States to treat diabetes in 2017, has found an international market for people trying to lose weight.
Despite its cost, the drug has soared in popularity in Kosovo, a country of 1.7 million.
While Kosovo authorities have not sanctioned the drug's use for weight loss, they have noted their limited means to confront use of a drug widely available in the country.
Merita Emini-Sadiku, who heads the Kosovo university hospital's endocrinology clinic, said the cost of the drug had soared.
"The monthly dose used to be 75-80 euros ($85-91), while now it is 130-140 euros ($147-159), probably due to high demand," she said.
But she warned that "Ozempic has side effects that people are not aware of".
Ozempic use can potentially cause issues including thyroid cancer, pancreatitis, gastroparesis and bowel obstruction, according to the latest studies.
- 'Constant demand' -
Meant to treat Type 2 diabetes -- of which the WHO says Kosovo has lower than average levels -- the drug regulates blood sugar levels but also helps suppress hunger, leading to a lower calorie intake.
As a result, its potentially cancerous complications have done little to stem the drug's popularity or availability.
"I checked a lot of pharmacies in Kosovo and I noticed that Ozempic is very easy to get," said Kadriu, adding that pharmacists even suggested she gradually increase her dosage.
A worker at a pharmacy in the capital Pristina's downtown, who asked to remain anonymous, said she had trouble recalling when someone last came into her pharmacy to buy Ozempic with a diabetes prescription.
"But we have a constant demand for Ozempic without a prescription. You can guess why," she said.
Given its availability, Emini-Sadiku said authorities should exercise greater control over Ozempic's distribution.
But Bujar Vitija, a journalist specialising in health, said that would be tricky to achieve given Kosovo's poor health record-keeping.
"Unfortunately there is no data," Vitija said.
With 1,500 to 1,600 private pharmacies in Kosovo, the country's 20 pharmaceutical inspectors have their work cut out for them, he added.
- Ozempic 'every day' -
While Kosovo has lower levels of obesity than the European average, more than 57 percent of the population is overweight and 20 percent is clinically obese, according to a 2019 World Health Organization report.
And women, who are more likely to face societal pressure to be thin, were 66 percent more likely to be obese than men, the WHO report found.
But not every Kosovar who has used Ozempic had the best experience with the drug.
"I took Ozempic on the advice of a doctor for two years but it had no effect," said 48-year-old merchant Lulzim Rrahmani, adding that three of his relatives even experienced "a negative effect of the drug".
"It was just a waste of money and time."
Given the risk of side effects, Emini-Sadiku said Ozempic was "by no means to be taken without a doctor's prescription".
Yet Kadriu said she would not be deterred, adding that she saw colleagues taking the drug "every day at work".
"I don't see any symptom that would deter me."
N.Schaad--VB